Expression of FAM134B in liver cancer and its association with prognosis: An analysis based on data mining

• Main Author: ZHONG Lanhai
• Format: Article
• Language: zho
• Published: Editorial Department of Journal of Clinical Hepatology 2019-11-01
• Series: Linchuang Gandanbing Zazhi
• Online Access: http://www.lcgdbzz.org/qk_content.asp?id=10323

ObjectiveTo investigate the expression of FAM134B in liver cancer and its association with clinicopathological features and prognosis. MethodsData mining was performed for Oncomine, Human Protein Atlas, TCGA, and Kaplan Meier-Plotter databases to analyze the expression of FAM134B in liver cancer, and the association of the expression of FAM134B with clinicopathological characteristics and prognosis was analyzed. The chi-square test was used for comparison of categorical data between groups, and the Kaplan-Meier method was used to investigate the association between FAM134B expression and prognosis of liver cancer. ResultsAs for normal tissue, the highest expression level of FAM134B was found in the kidney, and the expression of FAM134B in the liver ranked 9th; as for tumor tissue, the highest expression of FAM134B was found in renal cancer, and the expression of FAM134B in liver cancer ranked 11th. A total of 147 studies found a significant difference in FAM134B expression, and there was a significant difference in FAM134B expression between various tumors. FAM134B expression in liver cancer tissue was lower than that in normal liver tissue. FAM134B protein was localized in the endoplasmic reticulum, and its expression was associated with age of onset of liver cancer patients, liver cirrhosis, alpha-fetoprotein, race, and degree of tumor differentiation (all P＜0.05). FAM134B expression was associated with the overall survival rate of liver cancer patients (hazard ratio ［HR］=0.67, 95% confidence interval ［CI］: 0.47-0.95, P=0.026) and had significant influence on the prognosis of the Asian population (HR=0.40, 95%CI: 0.22-0.74, P=0.003), while it had no significant influence on the prognosis of the Caucasian population (HR=0.65, 95%CI: 0.40-1.05, P=0.076). ConclusionThere is a significant difference in the expression of FAM134B between tumors, with a low expression in liver cancer. FAM134B protein is localized in the endoplasmic reticulum, and its low expression is associated with several malignant phenotypes of liver cancer and the low overall survival rate.